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Abstract
Background: With the present study we introduce a novel and simple biomaterial able to induce
regeneration of bone. We theorized that nourishing a bone defect with calcium and with a large
amount of activated platelets may initiate a series of biological processes that culminate in bone
regeneration. Thus, we engineered CS-Platelet, a biomaterial based on the combination of Calcium
Sulfate and Platelet-Rich Plasma in which Calcium Sulfate also acts as an activator of the platelets,
therefore avoiding the need to activate the platelets with an agonist.
Methods:  First, we tested CS-Platelet in heterotopic (muscle) and orthotopic (bone) bone
regeneration bioassays. We then utilized CS-Platelet in a variety of dental and craniofacial clinical
cases, where regeneration of bone was needed.
Results: The heterotopic bioassay showed formation of bone within the muscular tissue at the site
of the implantation of CS-Platelet. Results of a quantitative orthotopic bioassay based on the rat
calvaria critical size defect showed that only CS-Platelet and recombinant human BMP2 were able
to induce a significant regeneration of bone. A non-human primate orthotopic bioassay also
showed that CS-Platelet is completely resorbable. In all human clinical cases where CS-Platelet was
used, a complete bone repair was achieved.
Conclusion: This study showed that CS-Platelet is a novel biomaterial able to induce formation
of bone in heterotopic and orthotopic sites, in orthotopic critical size bone defects, and in various
clinical situations. The discovery of CS-Platelet may represent a cost-effective breakthrough in
bone regenerative therapy and an alternative or an adjuvant to the current treatments.
Background
On January 13, 2000 The Bone and Joint Decade was for-
mally launched at the World Health Organization head-
quarters in Geneva, Switzerland [1,2]. The Bone and Joint
Decade has been endorsed by the United Nations, 54 gov-
ernments, and more than 750 organizations, medical
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groups, and journals worldwide. The ultimate goal is to
improve quality of life for people with musculoskeletal
conditions and to advance understanding and treatment
of these conditions through research, prevention, and
education. As musculoskeletal conditions are a leading
cause of disability in the United States, costing the Amer-
ican society an estimated $254 billion every year [2], on
March 21, 2002 President George W. Bush also signed a
proclamation designating the years 2002–2011 as the
Bone and Joint Decade in the United States [3]. The proc-
lamation called upon the medical community "to pursue
research in this important area." The present study repre-
sents a novel endeavor towards the development of inno-
vative approaches in bone regenerative therapy.
Since Marshall Urist described bone formation by autoin-
duction [4] and by purified bone morphogenetic proteins
(BMPs) from bone [5], researchers have focused their
investigations on techniques for delivering BMPs in order
to induce bone regeneration. However, while it is true that
the delivery of recombinant BMPs promotes bone forma-
tion in animal models, it is also true that these results do
not translate consistently into human clinical trials [6-8].
Indeed, the biology of the regeneration of bone is com-
plex and involves the coordinated expression of growth
factors, inhibitory factors, adhesive proteins and specific
transcription factors [9]. For these reasons researchers are
now employing other approaches such as the combinato-
rial delivery of multiple BMPs via gene therapy [10].
Clearly, the therapy of bone regeneration is still at its early
stages and novel contributions are needed in order to
develop efficient treatments.
With the present work we introduce CS-Platelet, a novel
and simple biomaterial able to induce regeneration of
bone in a variety of clinical situations. Differing from the
approaches seen to date, in our work we hypothesized
that nourishing a bone defect with calcium, a major inor-
ganic constituent of bone, and with a large amount of acti-
vated platelets, representing a component of wound
healing, may initiate a series of biological processes that
culminate in bone regeneration. Indeed, platelets appro-
priately activated by an agonist such as thrombin or colla-
gen release numerous biologically active factors that are
involved in wound healing and in processes that culmi-
nate in parenchymal cell proliferation and tissue regener-
ation [11-15] (Table 1, Panel A). Thus, the appropriate
delivery of activated platelets may represent a true combi-
natorial delivery of multiple biological factors for tissue
regeneration.
Therefore, in our laboratories we have engineered CS-
Platelet, a combination of Calcium Sulfate (CS), a reser-
voir of resorbable calcium, and Platelet-Rich Plasma
(PRP), a pool of concentrated platelets suspended in
plasma. Previous studies have shown that within CS-
Platelet, CS is able to activate the platelets present in the
PRP without the need for an agonist [16], and to carry and
release growth factors in a time-dependent manner [17].
Thus, CS-Platelet is a candidate biomaterial for bone
regeneration because it is able to sustain over time the
nourishment of the bone defects via the combinatorial
delivery of calcium and platelets' multiple biological fac-
tors. The main focus of the present study was to systemat-
ically test CS-Platelet in heterotopic (muscle) and
quantitative orthotopic (bone) bone regeneration bio-
assays. In addition, to evaluate its clinical features, CS-
Table 1: Panel A: List of the biologically active factors released by activated platelets. Panel B: Protocol for the preparation of PRP in 
each bioassay. The amount of blood collected, the centrifugal force, and the final PRP volume are shown.
Panel A
Biologically active factors released by the activated platelets11–15
ADP, ATP, Serotonin, Platelet-derived Growth Factor (PDGF), Transforming Growth Factor-β1 (TGF-β1), Connective Tissue Activating Peptide III 
(CATP III), Insuline-like Growth Factor-1 (IGF-1), Epidermal Growth Factor (EGF), Vascular Endothelial Growth Factor (VEGF), basic Fibroblast 
Growth Factor (bFGF), Angiopoietin-2 (Ang-2), Thrombospondin, Factor V, Factor XI, Factor XIII, Platelet-derived endothelial cell growth factor 
(PDECGF), Osteocalcin, and adhesive proteins such as Fibrinogen, Fibronectin, von Willebrand Factor (vWF), and P-Selectin.
Panel B
Bioassay Collected Blood 
(final volume, including 
anticoagulant)
Collection site First spinning (RCF) Second spinning 
(RCF)
PRP 
volume
Heterotopic bioassay (Ferret) 5 ml Jugular vein 40 g for 20' 235 g for 10' 250 μl
Orthotopic bioassay (Rat) 3 ml Jugular vein 380 g for 2'15" 380 g for 5' 75 μl
Orthotopic bioassay (Non-human primate) 30 ml Cephalic vein 1130 g for 2'15" 1130 g for 5' 1.5 ml
Clinical cases (Homo sapiens) 20 ml Cephalic vein
Basilic vein
Median cubital vein
1130 g for 2'15" 1130 g for 5' 1 mlJournal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
Page 3 of 13
(page number not for citation purposes)
Platelet was tested in a qualitative non-human orthotopic
bioassay and in 5 dental and craniofacial clinical cases,
where regeneration of bone was necessary.
Methods
Preparation of Platelet-Rich Plasma
Platelet-Rich Plasma (PRP) is derived from autologous
blood and is defined as a certain volume of plasma that
has a platelet concentration several fold above the physi-
ologic levels. In the present study we consistently used
PRP with a high concentration of platelets (8–10 fold
above the physiologic levels). The preparation of PRP,
including the amount of blood collected, the centrifugal
forces, and the final volume of the obtained PRP was opti-
mized for each bioassay in order to obtain that concentra-
tion (see Table 1, Panel B for details). The concentration
of platelets in whole blood and in the PRP was deter-
mined manually using a Petroff-Hausser counting cham-
ber (improved Neubauer, cell-depth of 0.02
mm)(Hausser Scientific, USA). In all cases, PRP was pre-
pared from autologous blood by a 2-step centrifugation
process following previously published protocols [12,18]
with some modifications (Fig. 1). Briefly, aliquots of
whole blood were collected in tubes containing acid-cit-
rate-dextrose as an anti-coagulant (0.163 ml per 1 ml of
blood) (Fig. 1, step 1). Immediately after being drawn,
blood was centrifuged to separate red blood cells (RBCs)
from platelets and plasma (Fig. 1, step 2). Then, the super-
natant composed of platelets and plasma was collected
and centrifuged again in order to pellet the platelets (Fig.
1, step 3). After this second centrifugation, the platelets
were re-suspended in an appropriate volume of plasma
(Fig. 1, step 4, 5) to achieve a platelet concentration equal
to 8–10 fold above the physiologic levels.
Preparation of CS-Platelet
The commercially available powder form of Calcium Sul-
fate (CS) is the product of partial dehydration of gypsum,
which produces CS hemihydrate (CaSO4·1/2 H2O).
When the hemihydrate is mixed with water in the correct
proportions, a suspension is formed that is initially fluid
and workable; then, the hemihydrate completely precipi-
tates until crystals of dihydrated solid CS are formed. This
is an exothermic setting reaction during which 1 g of
hemihydrate CS combines with 186 μl of water [19,20].
Similarly, as described in previous studies [16], CS-Plate-
let was prepared by mixing hemihydrate CS (Capset,
Lifecore Biomedical, Inc. USA for the animal bioassays,
and Surgiplaster, ClassImplant, s.r.l. Italy for the human
clinical cases) with Platelet-Rich Plasma (PRP) in place of
water. To account for the viscosity of plasma and for the
platelet's volume, the powder (CS) to liquid (PRP) ratio
was adjusted to 1 g of CS to 240 μl of PRP. By mixing CS
with PRP a malleable paste was obtained and applied at
the surgical sites (Fig. 1, step 6). After 30 minutes CS-
Platelet crystallized becoming a solid and homogeneous
compound [16]. According to each experiment or clinical
case, the required amount of CS-Platelet was prepared by
mixing CS with PRP in the ratio previously mentioned.
Bioassays
All animal bioassays presented hereafter were conducted
in accordance with the Institutional Animal Care and Use
Committee (IACUC) of the University at Buffalo.
Heterotopic (muscle) bioassay
A heterotopic bioassay [21,22] was used to test the oste-
oinductive activity of CS-Platelet (Fig. 2). To this end, 120
μl of PRP or 120 μl of double distilled sterile water were
mixed with 500 mg of CS to prepare samples of CS-Plate-
let or CS. Then, 4 samples of CS-Platelet and 4 samples of
CS were implanted into the triceps brachii and biceps
femoris of a ferret (Fig. 2A). To help with post-surgical
localization, a tattoo (1% India ink in 25 ul PBS) was per-
formed at the mesial aspect of each implantation. Man-
agement of post-operative pain included subcutaneous
administration of buprenorphine (0.01 mg/kg body
weight). At 4 weeks post-implantation, x-rays were
obtained from each muscle (10 MA, 78 kVp, 1/15 of a sec-
ond impulse, anode-film distance = 20 cm) (Fig. 2B).
Then, histological specimens were retrieved, demineral-
ized in 14% EDTA for 10 days, and processed for tissue
sectioning (4 μm) and staining (Hematoxylin and Eosin)
(Fig. 2C–L).
Rat orthotopic (bone) bioassay
Using the 8 mm rat calvaria critical size defect (CSD)
model of bone regeneration [23], the efficacy of CS-Plate-
let for in vivo bone regeneration was compared to the effi-
cacy of other biomaterials (Fig. 3 and Fig. 4). The 8 mm
diameter craniotomy defects were created with a trephine,
avoiding perforation of the dura mater. Then, the created
bone defects were filled with the chosen biomaterial.
Briefly, 35 female adult Sprague-Dawley rats (275 g) were
randomly divided into 7 groups of 5 rats each: 1) no fill-
ing biomaterial (Negative); 2) 100 mg of CS with 24 μl of
double distilled sterile water (CS); 3) 24 μl of PRP acti-
vated by thrombin and CaCl2 in accordance with previ-
ously published protocols [12,24] (PRP); 4) 100 mg of CS
and 24 μl of PRP (CS-Platelet); 5) 6.8 mg of collagen [25]
(Coll); 6) 5 μg of human recombinant BMP2 (Cell Sci-
ences, Inc. USA) and 6.8 mg of collagen [25,26]
(rhBMP2); and 7) no surgery performed (External con-
trol). The rhBMP2 group (5 μg of rhBMP2 per cranial
defect) represents a gold standard treatment for the regen-
eration of the 8 mm rat calvaria defect model [21,26] and
in this study is used as comparative positive control. 100
mg of CS powder was determined to be the amount of CS
required to completely fill the 8 mm cranial defect. After
implantation of the biomaterials, the soft tissues wereJournal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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closed with skin staples. Management of post-operative
pain included subcutaneous administration of buprenor-
phine (0.01 mg/kg body weight). Rats were euthanized by
CO2 asphyxiation 8 weeks after surgery. The craniotomy
sites with 10 mm contiguous bone were recovered from
the skull and placed in a fixative solution (20 ml of RNA-
Later, Ambion Inc, USA). All explanted calvaria were
scanned using a Scanco Medical AG (Bassersdorf, Switzer-
land) μCT 40 system. Specimens were scanned using an
18 μm isotropic voxel size (FOV: 36.8; 2048 × 2048 image
matrix) and 2000 projections/360 degrees [26]. Mineral-
ized bone tissue was segmented from non-mineralized tis-
sue by applying a gauss filter (sigma:1.6; support:3.0) and
using a threshold of 21% of maximum gray scale value.
The new bone formation was analyzed by extracting the
region of new bone in the critical size defect using semi-
automated contouring. The volume (mm3), the surface
(mm2), and the density (mg/mm3) of the newly regener-
ated bone were measured by a blinded operator. Statisti-
cal power was calculated on previous bone regeneration
calvaria defect studies [26] and differences among groups
were statistically analyzed by ANOVA followed by the
Fisher LSD multiple comparison test (significance level of
0.01). After tomography quantification, the specimens
Preparation of CS-Platelet Figure 1
Preparation of CS-Platelet: Step 1: aliquots of whole blood (as indicated in Table 1) were collected in tubes containing 
acid-citrate-dextrose as an anti-coagulant. Step 2: immediately after being drawn, blood was centrifuged (see Table 1) to sepa-
rate RBCs from platelets and plasma. Step 3: The supernatant composed of platelets and plasma was collected and centrifuged 
again (see Table 1) in order to pellet the platelets. Step 4 and 5: After this second centrifugation, the platelets were re-sus-
pended in an appropriate volume of autologous plasma to achieve a platelet concentration 8–10 fold above the physiologic lev-
els. (Step 6): CS (powder) was mixed with PRP (liquid) in a ratio of1 g of CS to 240 μl of PRP.Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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were processed for non-demineralized tissue sectioning (7
μm) and staining (Goldner's Trichrome).
Non-human primate orthotopic (bone) bioassay
To test its clinical features and the histological outcomes,
CS-Platelet was compared to demineralized freeze-dried
bone allograft (DFDBA) (American Red Cross, Tissue
Services, USA) (Fig. 5). One adult male non-human pri-
mate (Macacus rhesus) was used. Prior to the surgical
extraction of the maxillary and mandibular first premo-
lars, first molars, and third molars the animal was prop-
erly anesthetized. 30 ml of blood were collected for the
preparation of 1.5 ml of PRP (see Table 1 for details).
Then, using a split-mouth design, the right extraction
sockets were each filled with CS-Platelet (1 g of Calcium
Sulfate and 240 μl of PRP) and the left extraction sockets
with human DFDBA (0.5 cc, American Red Cross – Tissue
Services, Arlington VA). Management of post-operative
pain included intramuscular administration of buprenor-
phine (0.01 mg/kg body weight) every 6–12 hrs for 4
days. Eight weeks after surgery, the animal was sacrificed
and block sections of the grafted sites were collected, dem-
ineralized in 14% EDTA for 10 days, and processed for tis-
sue sectioning (4 μm) and staining (Hematoxylin and
Eosin).
Human Clinical Cases
To test its clinical potentials, CS-Platelet was used in five
human clinical dental cases (Fig. 6). In all patients treated
(age group: 35–55 year old), the platelet count was within
the normal limits and the medical and dental history
revealed no significant contraindications to bone regener-
ative therapy. In all cases presented regeneration of bone
was needed in order to either augment the amount of the
preexisting bone for subsequent implantation of titanium
implants (Augmentation cases: cases 1–3) or to augment
the amount of bone surrounding a preexisting titanium
implant to preserve the implant (Preservation cases: cases
4 and 5). Clinical cases consisted of: 1) Augmentation of
extraction socket upon extraction of tooth # 8 (Fig. 6A–
D), 2) Ridge augmentation therapy in area of teeth # 5–6
(Fig. 6E–H), 3) Sinus augmentation therapy (induced
Heterotopic (muscle) bioassay in ferrets Figure 2
Heterotopic (muscle) bioassay in ferrets: (A): The biceps femoris of a ferret is shown. A sample of CS-Platelet and a sam-
ple of CS were implanted in the muscle tissue. (B): Four weeks after implantation the x-ray evaluations showed the presence of 
radio-opaque formations only in correlation with the implantations of CS-Platelet. (C, E-H): At the histological evaluation, the 
radio-opaque formation appeared as an ossicle formed by trabecular bone. (D, I-L): No bone formation was observed in corre-
spondence with the implantations of Calcium Sulfate alone. Hematoxylin and Eosin staining.Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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bone formation within the right maxillary sinus) prior
insertion of a titanium implant in area of teeth # 3–4 (Fig.
6I–L), 4) Regeneration of bone around the exposed
threads of a titanium implant positioned are of tooth # 9
(Fig. 6M–P), and 5) Peri-implantitis around titanium
implant in position of tooth # 30 (Fig. 6Q–T). Prior to
implantation of CS-Platelet the surgical recipient sites
were freed of soft tissue tags and contaminated bone (tis-
sue debridement). In the case of the sinus augmentation
therapy, the schneiderian membrane was carefully ele-
vated and CS-Platelet was implanted between the mem-
brane and the floor of the sinus. In all other cases, after
tissue debridement, CS-Platelet was simply applied in
order to completely fill the bone defect. Then, the surgical
Orthotopic (bone) bioassay in rats – From left to right: Microcomputed Tomography (μCT) images, sagittal histological sec- tions, higher magnifications of histological sections (100× and 400× original magnifications) Figure 3
Orthotopic (bone) bioassay in rats – From left to right: Microcomputed Tomography (μCT) images, sagittal 
histological sections, higher magnifications of histological sections (100× and 400× original magnifications). 
Eight weeks after implantation in the 8 mm rat critical size defects, only CS-Platelet and rhBMP2 showed a regeneration of 
bone extended at the center of the defects. In all other groups a limited regeneration of bone was seen only at the periphery 
of the defects. Goldner's trichrome staining: nuclear chromatin (brown-black), cytoplasm (bright red), erythrocytes (orange), 
collagen (light green), mineralized bone (green), osteoid (red).Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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Orthotopic (bone) bioassay in rats – Quantitative analysis of Tomography Data Figure 4
Orthotopic (bone) bioassay in rats – Quantitative analysis of Tomography Data. Volume (A): only CS-Platelet, 
rhBMP2, and the External control showed a statistically significant difference from the negative control (p < 0.001). Surface 
area (B): only CS-Platelet, rhBMP2, and the External control showed a statistically significant difference from the negative 
control (p < 0.001). Density (C): all treatment groups showed a density of the regenerated bone statistically different from 
the density of the bone normally present in an area of 8 mm of the calvaria (External control)(p < 0.001).Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
Page 8 of 13
(page number not for citation purposes)
wounds were sutured in order to achieve healing by first
intention. Management of post-operative pain included
administration of ibuprofen (400 mg t.i.d. p.r.n.). Clinical
and radiographical re-evaluations were performed at 6
months. The human clinical cases were conducted in pri-
vate dental practices on volunteers who gave written
informed consent. Each subject was also informed that
data concerning the case would be submitted for publica-
tion.
Results
Heterotopic (muscle) bioassay
Four weeks after implantation of CS or CS-Platelet in the
triceps brachii and biceps femoris of a ferret (Fig. 2A), the
x-ray evaluations showed the presence of radio-opaque
formations only at the sites of the CS-Platelet implanta-
tions (Fig. 2B). Upon histological evaluation, bone forma-
tion in the form of an ossicle was noted (Fig. 2C and 2E–
H). Highly vascularized trabecular bone associated with
highly vascularized bone marrow rich of reticular cells
was observed (Fig. 2E and 2G, red arrows). In addition, at
the periphery of the bone nodule endochondral bone for-
mation was noticeable (Fig. 2F, blue arrow), testifying a
peripheral functional remodeling of mesenchymal tissue.
No encapsulation of the bone nodule by chronic inflam-
mation was observed. The presence of numerous active
osteoblasts forming a rim of cells in the process of laying
down osteoid (Fig. 2G and 2H, purple arrows), numerous
osteocytes incorporated in the newly formed bone (Fig.
2G and 2H, black arrows), and osteoclasts forming How-
ship's lacunae (Fig. 2H, green arrow) confirm the high
vitality of the generated bone nodule. No bone formation
was observed at the site of the implantations of CS alone
(Fig. 2D). CS was not completely resorbed and residual
small crystals of CS were seen within the tissue. (Fig. 2L,
grey arrow). The amount of residual CS is modest and the
crystals are too dispersed to be shown by our x-ray evalu-
ation (Fig. 2B). A foreign body reaction with both chronic
(multinucleated-giant cells) and acute inflammatory
response (polymorphonucleated) were also noticed (Fig.
2K,L, yellow arrows). Importantly, in both the CS-Platelet
and CS cases, no signs of malignancy were observed.
Rat orthotopic (bone) bioassay
Eight weeks after implantation in the 8 mm rat critical size
defects, only CS-Platelet and rhBMP2 showed a regenera-
tion of bone extended at the center of the defects (Fig. 3).
In both these groups, areas of vascularized bone marrow
are evident, and numerous osteocytes are present within
the newly formed bone, testifying the vitality of the regen-
erated tissue. Osteoblasts present at the osteoid interface
(osteoid tissue is stained in red with Goldner Trichrome)
are in the process of laying down osteoid matrix. In all
other groups, a limited regeneration of bone was seen
only at the periphery of the defects (Fig. 3). As expected,
in these cases bone regenerated only at the margins with
fibrotic tissue always present at the center of the defects. In
both the CS-Platelet and CS groups the implanted bioma-
terial is not completely resorbed (Fig. 3). Upon quantifi-
cation and statistical analysis of the volume of bone
Non-human primate orthotopic (bone) bioassay – Histology Figure 5
Non-human primate orthotopic (bone) bioassay – Histology. (A-D): samples of alveolar bone implanted with DFDBA. 
(E-H): Samples of alveolar bone implanted with CS-Platelet. All grafted sites, whether implanted with CS-Platelet or with 
DFDBA, showed regeneration of trabecular bone. In the sites grafted with DFDBA some residual biomaterial was still visible 
(B, black arrows). Hematoxylin and Eosin staining. (A and E, 40× original magnification). (B-D and F-H, 100× original magnifica-
tion).Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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regenerated within the 8 mm defect (Fig. 4A), only CS-
Platelet, rhBMP2, and the External control showed a sta-
tistically significant difference from the negative control
(p < 0.001). Evidently, CS alone (CS), activated PRP alone
(PRP), and Collagen alone (Coll) are able to regenerate
the same amount of bone that is regenerated when the
defect is left unfilled (Negative)(non statistical significant
difference). More specifically, CS-Platelet regenerated a
Human clinical cases (from the top to the bottom) Figure 6
Human clinical cases (from the top to the bottom). Augmentation cases: (A-D): Augmentation of extraction socket 
upon extraction of tooth # 8. (E-H): Ridge augmentation therapy in area of teeth # 5–6. (I-L): Sinus augmentation therapy 
(induced bone formation within the right maxillary sinus) prior insertion of a titanium implant in area of teeth # 3–4. Preser-
vation cases: (M-P): Regeneration of bone around the exposed threads of a titanium implant positioned in area of tooth # 9. 
(Q-T): Regeneration of bone around a titanium implant in position of tooth # 30 affected by peri-implantitis.Journal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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volume of bone approximately 2/3 the volume regener-
ated by rhBMP2 (statistically significant difference, p <
0.001) and approximately 1/2 the volume present in an
area of 8 mm of the normal calvaria (External control)
(statistically significant difference, p < 0.001). Upon
quantification and statistical analysis of the surface area of
the bone regenerated within the 8 mm defect (Fig. 4B),
only CS-Platelet, rhBMP2, and the External control
showed a statistically significant difference from the nega-
tive control (p < 0.001). However, the surface area of the
bone regenerated by CS-Platelet was not statistically dif-
ferent from the one regenerated by rhBMP2 (p = 0.26) and
the one normally present in an area of 8 mm of the nor-
mal calvaria (External control) (p = 0.68). Again, CS alone
(CS), activated PRP alone (PRP), and Collagen alone
(Coll) are able to regenerate the same surface area of bone
that is regenerated when the defect is left unfilled (Nega-
tive)(non statistically significant difference). Upon quan-
tification and statistical analysis of the density of the bone
regenerated within the 8 mm defect (Fig. 4C) all treatment
groups showed a density of the regenerated bone statisti-
cally different from the density of the bone normally
present in an area of 8 mm of the normal calvaria (Exter-
nal control)(p < 0.001).
Non-human primate orthotopic (bone) bioassay
Eight weeks after implantation of CS-Platelet or deminer-
alized freeze-dried bone allograft (DFDBA) in the tooth-
extraction sockets, healing was shown to be uneventful
and no bone loss or recession was reported at the adjacent
teeth. In both cases, histologically, the overlying mucosa
was fully formed with stratified squamous epithelium
(Fig. 5A and 5E, blue arrows). Moreover, all grafted sites,
whether implanted with CS-Platelet or with DFDBA,
showed regeneration of trabecular bone (Fig. 5B–D and
5F–H, red arrows) associated with fibrofatty vascularized
bone marrow (Fig. 5C–D and 5G–H, green arrows).
Importantly, the grafted sites with DFDBA showed some
residual biomaterial (Fig. 5A, black arrows), whereas no
residual biomaterial was found in the sites grafted with
CS-Platelet. In both cases, no signs of malignancy and no
signs of chronic or acute inflammation were evident.
Human Clinical Cases
Six months after implantation of CS-Platelet, the patients
were seen for re-evaluation of the bone regenerative ther-
apy (Fig. 6). In all augmentation cases (Cases 1–3), the
surgical re-opening showed complete bone repair within
the treated area so that placement of titanium implant was
achievable and successful (Fig. 6D,H and 6L respectively).
The radiographical exam, when present (Fig. 6L), also
confirmed the clinical evaluation, showing an area of
radio-opaque bone repair within the bone defect. The
Exposed threads therapy and the Peri-Implantitis (Preser-
vation cases: cases 4 and 5) showed a successful bone
repair with the achievement of healthy clinical status that
allowed for the preservation of the previously implanted
titanium implants (Fig. 6P and 6T respectively).
Discussion
Prior studies showed that CS and PRP, used separately,
have limited degrees of success in bone regenerative ther-
apy [27-33]. Although safely used in orthopedics for more
than 100 years [27], CS alone has only been effective in
treatment of non-critical (union) size bone defects
[28,29]. More recently, CS has been proposed as a graft
barrier rather than a true bone regenerative biomaterial
[30,31,34]. PRP has shown some degree of effectiveness
only when used in combination with certain biomaterials.
For instance, Marx et al [24] showed that a significantly
greater percentage of bone regeneration can be achieved
when autogenous cancellous bone grafts were combined
with PRP. Confirming the results of this study, another
animal study showed that PRP may be beneficial when
applied in combination with autologous bone [35]. A ran-
domized, split mouth, double-masked clinical study [36]
showed that the addition of PRP to a bovine derived
xenograft to treat human intrabony defects significantly
improved the clinical outcome. Another recent study eval-
uated the effect of PRP in the treatment of periodontal
intrabony defects in humans [37] and showed that the
combination of PRP with bovine porous bone mineral led
to significantly favorable clinical improvements. The
unfavorable results seen in other studies [32,33] may be
due to the incompatible combination of PRP with the
chosen biomaterial or to the fact that the concentration of
platelets in PRP may vary according to the procedure used
for its preparation [32]. It is still not clear whether low
concentrations of platelets (2–3 fold above the physio-
logic levels) are more effective in regenerating bone than
moderate (5 fold) or high (8–10 fold) concentrations, as
recent in vitro studies [38,39] are inconsistent with previ-
ous in vivo studies [40]. In the present study we consist-
ently used PRP with a concentration of platelets 8–10 fold
above the physiologic levels.
Our work provides clear evidence that CS and PRP when
opportunely combined (CS-Platelet) are able to induce
regeneration of bone in critical size (nonunion) bone
defects. This is due to the unique characteristics of CS-
Platelet that CS alone and PRP alone do not possess. In
fact, previous studies [16] showed that the exothermic
reaction generated by the mixture of CS with PRP (CS-
Platelet) activates the platelets contained within the PRP
without the need for an agonist. Due to this activation
process, the multiple biological factors released by the
activated platelets are present in high concentrations and
in their physiologically high ranges within CS-Platelet.
The same studies also showed that CS-Platelet maintains
all the optimal clinical advantages associated with CS, inJournal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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that CS-Platelet is initially moldable and later solidifies,
maintaining the space/scaffold needed by the bone regen-
erative process. Later [17] it was also proven that CS can
slowly release recombinant human Platelet-Derived
Growth Factor (rhPDGF-BB) over time, therefore support-
ing the hypothesis that CS-Platelet behaves as time-con-
trolled releasing matrix for all the platelet derived factors.
Because a major concern in delivery of the growth factors
to the site of bone healing has always been their short
half-lives [41], CS-Platelet represents a novel biocompati-
ble delivery system for growth factors. Thus, CS-Platelet is
a biomaterial that contains several components and qual-
ities ideal for bone regeneration: 1) high quantities of cal-
cium, 2) physiologically high concentrations of platelet's
growth factors, 3) physiologically high concentrations of
platelets' and plasma's adhesive proteins, 4) time-control-
led release of growth factors, 5) initial malleability, 6)
subsequent solidification, and 7) space maintaining prop-
erties. It is therefore not surprising that the heterotopic
bioassay showed that CS-Platelet is an osteoinductive bio-
material (able to induce the formation of bone in muscle)
as opposed to a simple osteoconductive biomaterial
(serve only as scaffold for bone formation). In addition,
the orthotopic bioassay in rats confirmed the osteoinduc-
tive quality of CS-Platelet. In nonunion defects CS-Platelet
induced the formation of bone, in terms of volume, equal
to approximately 2/3 the bone induced by the gold stand-
ard treatment (rhBMP2). Moreover, in terms of surface
area of the regenerated bone, CS-Platelet and rhBMP2 are
comparable and also equivalent to the surface area of the
normal calvaria (External control). Yet, the density of the
regenerated bone in both CS-Platelet and rhBMP2 groups
is lower than that observed in normal calvaria (External
control). This indicates that after 8 weeks of healing the
regenerated bone is still substantially different from the
normal bone and that a longer healing time may be
needed to achieve full density. In our quantitative rat
orthotopic bioassay, the volume of bone regenerated by
the delivery of rhBMP2 exceeds the volume regenerated by
CS-Platelet. This may be due to the fact that human
rBMP2 when implanted in heterologous bone defects,
such as those used in animal studies, is more effective
[42]. Noticeably, it has also been reported that the suc-
cessful use of human rBMPs in animals does not translate
consistently into human clinical trials [6-8].
The quantitative orthotopic assay also showed that CS
alone and the activated PRP alone are able to sustain only
a minimal, peripheral, regeneration of bone. It is not sur-
prising that CS alone and PRP alone are not able to induce
any significant regeneration of bone when compared to a
negative control. Clearly, CS lacks the growth factors pro-
vided by the PRP while PRP requires CS as an efficient car-
rier for its growth factors. The presence of a layer of bone
on the bottom of the defect and the presence of a layer of
un-resorbed CS-Platelet over the regenerated bone also
shows that CS-Platelet acts as a functional barrier. A func-
tional barrier, by impeding the migration of the epithelial
cells from the skin into the bone defect, facilitates the
bone regeneration process that is sustained only by osteo-
competent cells [43]. Thus, we speculate that CS-Platelet,
by acting as an epithelial barrier, facilitates the formation
of bone that is sustained by the pervascular mesenchymal-
type cells of the dura mater, on the bottom of the defect
[44]. Importantly, although we did not measure the level
of vascularization, in both the heterotopic and the ortho-
topic bioassays the qualitative histological evaluation of
the CS-Platelet grafted sites consistently showed an ele-
vated number of blood vessels. The ability of a biomate-
rial to induce vascularization is highly desirable in bone
tissue engineering because it represents the means for
nourishing and supporting the migration of competent
cells.
The important conclusions of the present study are based
on the heterotopic bioassay and on the quantitative rat
orthotopic bioassay. However, in order to test the clinical
features of CS-Platelet, we designed the qualitative ortho-
topic non-human bioassay and we tested CS-Platelet in
some clinical cases. Significantly, we report that CS-Plate-
let in 6 tooth-extraction sockets of a non-human primate
is completely resorbed after 8 weeks. This, together with
no histological signs of malignancy or chronic and acute
inflammation makes CS-Platelet a safe biomaterial suita-
ble for various bone regenerative therapies. Confirming
these conclusions, in the human clinical cases where CS-
Platelet was tested we observed repair of hard tissues. The
augmentation therapies showed reconstitution of the
anatomy of the alveolar ridges and the preservation ther-
apies showed the ability of CS-Platelet to treat bone loss
around titanium implants. The clinical efficacy of CS-
Platelet correlated well with its clinical viability as CS-
Platelet, thanks to its physical attributes, was easy to pre-
pare and simple to be applied within the bone defects.
Conclusion
The heterotopic bioassay and the quantitative rat ortho-
topic bioassay allowed us to conclude that CS-Platelet is
osteoinductive and regenerates bone in critical size bone
defects. The orthotopic non-human bioassay and the clin-
ical cases presented represent a limited (in sample size)
and yet significant qualitative analysis of the in vivo effi-
cacy of CS-Platelet.
Newly developed biomaterials intended for clinical use in
bone regenerative therapy should be osteoinductive, easy
to handle, suitable for an in situ application, available on
a large scale, safe, and cost effective. CS-Platelet, based on
the inexpensive Calcium Sulfate and on the patient's own
PRP, meets all of these requirements. In addition, becauseJournal of Translational Medicine 2007, 5:13 http://www.translational-medicine.com/content/5/1/13
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CS-Platelet is initially fluid and later solidifies, it may be
used as an injectable biomaterial for minimally invasive
surgeries. Thus, the discovery of CS-Platelet may represent
a cost-effective breakthrough in translational medicine
and an alternative or an adjuvant to the currently available
bone regenerative therapies.
Further and more extended animal and human studies
may be needed to effectively translate the findings of the
present study into an established and effective protocol
for bone regenerative therapy.
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